Physician profile

Bridget Doolittle

Physician Assistant · Princeton, NJ

NPI 1700447083

$849.48

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$246.81

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Heraeus Medical, LLC. $139.47 2021
Depuy Synthes Sales INC. $134.55 2021
Pacira Therapeutics, INC. $127.94 2021
Viiv Healthcare Company $124.98 2023 Apretude
Ultragenyx Pharmaceutical INC. $121.83 2023 Crysvita
Stryker Corporation $95.88 2021
Molnlycke Health Care US, LLC $56.38 2021
Bioventus LLC $22.31 2021
Horizon Therapeutics Plc $13.84 2021
Ferring Pharmaceuticals INC. $12.30 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Bridget Doolittle

$849.48

in general payments reported 2019-2025

Years
2021-2023
Top company
Heraeus Medical, LLC.

https://glasscript.com/doctor/10829649/bridget-doolittle

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.